AGP
TGTX icon

Artia Global Partners’s TG Therapeutics TGTX Stock Holding History

Artia Global Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-54,515
Closed -$1.97M – 71
2025
Q3 		$1.97M Hold
54,515
– – 0.31% 33
2025
Q2 		$1.96M Hold
54,515
– – 0.47% 24
2025
Q1 		$2.15M Hold
54,515
– – 0.54% 24
2024
Q4 		$1.64M Buy
+54,515
New +$1.56M 0.59% 26

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Artia Global Partners's TGTX Position: Q4 2025 in Review

Artia Global Partners sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 54,515 shares — an estimated $1.97M sold.

Artia Global Partners first reported a position in TGTX in Q4 2024 and held it in 4 quarters. The position peaked at $2.15M in Q1 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Artia Global Partners reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Artia Global Partners sold 54,515 TG Therapeutics shares in Q4 2025, an estimated $1.97M.
  • Artia Global Partners first reported a position in TG Therapeutics in Q4 2024 and held it in 4 quarters.
  • Artia Global Partners's TG Therapeutics position peaked at $2.15M in Q1 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Artia Global Partners's 13F filing for Q4 2025, filed 17 Feb 2026.